Compare Vanguard Real Estate Index Fund ETF (VNQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Real Estate Index Fund ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Real Estate Index Fund ETF trades at $90.53 (market cap $70.80B), while Vertex Pharmaceuticals Incorporated trades at $509.91 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Real Estate Index Fund ETF for 113 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VNQ | VRTX | |
|---|---|---|
Market Cap | $70.80B | $127.55B |
Volume | 6,073,580 | 1,487,944 |
52-Week High | $100.95 | $557.96 |
52-Week Low | $87.00 | $407.37 |
Typical Hold Time | 113 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQ trades at $90.50, up 2.04% today but facing a bearish technical trend with key support at $87. The ETF's fundamentals are obscured by missing valuation ratios, while sentiment is mixed amid rising interest rates pressuring REIT yields. Recent news highlights institutional buying but also concerns over dividend sustainability versus Treasury bills.
Outlook remains cautious due to interest rate sensitivity and sector oversupply risks. Opportunities exist for contrarian investors seeking long-term real estate exposure, but near-term headwinds from Fed policy and economic volatility warrant careful risk assessment.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
